2023
DOI: 10.24875/gmm.m20000361
|View full text |Cite
|
Sign up to set email alerts
|

Experience with the use of olaparib in patients with ovarian cancer

Abstract: Introduction: More than the twenty percent of ovarian cancers are hereditary, and most have BRCA mutations. The 30% of Mexican patients with the BRCA1 mutation have the BRCA1 gene exon 9-12del deletion founder mutation (BRCA1 ex9-12del). BR-CA-mutated tumors are more sensitive to PARP inhibitors such as olaparib. Objective: To show the clinical experience on the use of olaparib at Instituto Nacional de Cancerología in Mexico. Method: Ovarian cancer patients treated with olaparib from November 2016 to December … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 8 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?